Clearmind Medicine Inc. released real-world insights from its ongoing CMND-100 first-in-human clinical trial on July 13, 2026. The company reported promising data regarding the investigational compound's performance in early human subjects. Clearmind Medicine is a biopharmaceutical company focused on developing psychedelic-based medicines for neurological and psychiatric disorders.
